Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | POLE P286R |
Therapy | unspecified CTLA4 antibody + unspecified PD-1 antibody |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
POLE P286R | colorectal cancer | sensitive | unspecified CTLA4 antibody + unspecified PD-1 antibody | Preclinical | Actionable | In a preclinical study, the combination of a murine anti-CTLA4 antibody and a murine anti-PD1 antibody inhibited tumor growth in a syngeneic mouse model of colorectal cancer expressing POLE P286R (PMID: 35817971). | 35817971 |
PubMed Id | Reference Title | Details |
---|---|---|
(35817971) | Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. | Full reference... |